Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Jul 15:22:109-112.
doi: 10.1016/j.rmcr.2017.07.007. eCollection 2017.

Scleroderma-related interstitial lung disease

Sally Suliman  1 , Abdalhamid Al Harash  2 , William Neil Roberts  2 , Rafael L Perez  1   3 , Jesse Roman  1   3
Affiliations
Case Reports

Scleroderma-related interstitial lung disease

Sally Suliman et al. Respir Med Case Rep. .

Abstract

Scleroderma-related interstitial lung disease (SSc-ILD) is a pulmonary fibrosing disorder characterized by systemic inflammation and progressive scarring of the lungs that leads to respiratory failure. Although certain immunosuppressive therapies may slow disease progression, current treatment strategies are not curative; consequently, SSc-ILD continues to be a major cause of morbidity and mortality. We present four cases of SSc-ILD that emphasize the importance of early screening and detection, close follow-up, and aggressive management. We also highlight the need for well-conducted clinical trials designed to identify new and effective treatments.

Keywords: Immunosuppression; Progressive systemic sclerosis; Pulmonary fibrosis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Lung involvement in Ssc-ILD and related abnormalities. A, High resolution chest CT of patient of Case 1. B, High resolution chest CT scan of Care 2. C, High resolution chest CT scan of Care 3. D, High resolution chest CT scan of Care 4. E, Skin telangiectasia detected in Case 4. F, Barium swallow performed in Case 4 showing retention of fluid in esophagus.
See this image and copyright information in PMC

References

    1. Giacomelli R., Liakouli V., Berardicurti O., Ruscitti P., Di Benedetto P., Carubbi F., Guggino G., Di Bartolomeo S., Ciccia F., Triolo G., Cipriani P. Interstitial lung disease in systemic sclerosis: current and future treatment. Rheumatol. Int. 2017 - PubMed
    1. Rodnan G.P., Benedek T.G. A historical account of the study of progressive systemic sclerosis (diffuse scleroderma) Ann. Intern Med. 1962;57:305–319. - PubMed
    1. Furst D.E., Fernandes A.W., Iorga S.R., Greth W., Bancroft T. Epidemiology of systemic sclerosis in a large US managed care population. J. Rheumatol. 2012;39:784–786. - PubMed
    1. Hoyles R.K., Ellis R.W., Wellsbury J., Lees B., Newlands P., Goh N.S., Roberts C., Desai S., Herrick A.L., McHugh N.J., Foley N.M., Pearson S.B., Emery P., Veale D.J., Denton C.P., Wells A.U., Black C.M., du Bois R.M. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54:3962–3970. - PubMed
    1. Morales-Cardena A., Perez-Madrid C., Arias L., Ojeda P., Mahecha M.P., Rojas-Villarraga A., Carrillo-Bayona J.A., Anaya J.M. Pulmonary involvement in systemic sclerosis. Autoimmun. Rev. 2016;15:1094–1108. - PubMed

Publication types

LinkOut - more resources